Search results for "Colorectal neoplasms"

showing 10 items of 496 documents

Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use

2015

Objective The aim of this study was to compare the uptake of mail-delivered tests for colorectal cancer screening. We assessed the effect of an advance notification letter and a reminder letter, and analysed the proportion of inappropriately handled tests. Materials and methods Fifteen thousand randomly selected residents of Latvia aged 50–74 years were allocated to receive one of three different test systems: either a guaiac faecal occult blood test (gFOBT) or one of two laboratory-based immunochemical tests (FIT) – FOB Gold or OC-Sensor. Half of the target population received an advance notification letter; all nonresponders were sent a reminder letter. Results The uptake of screening was…

OncologyMalemedicine.medical_specialtygenetic structuresColorectal cancerReminder Systemseducationcolorectal cancer screeningfaecal occult blood testSpecimen HandlingRandom AllocationInternal medicinemedicinePostal serviceOriginal Articles: Colorectal CancerHumansPostal ServiceEarly Detection of CancerAgedRandom allocationGynecologyHepatologybusiness.industryImmunochemistryGastroenterologyMiddle AgedPatient Acceptance of Health Caremedicine.diseasefaecal immunochemical testCorrespondence as TopicLatviaadvance notification letterTest (assessment)Colorectal cancer screeninguptakeOccult BloodFemaleFaecal occult blood testbusinessColorectal NeoplasmsGuaiacEuropean Journal of Gastroenterology & Hepatology
researchProduct

Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with…

2002

Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid (FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer. However, the best palliative sequence of these substances is still unclear. After CPT-11 containing regimens the optimal salvage protocol has not yet been defined. Here, we retrospectively analysed the weekly ambulant combination of OXA with continuous FA/5-FU (FUFOX) after two different CPT-11 containing chemotherapeutic regimens. Patients: During October 1999 and May 2001, 20 patients (median 62; 48-74 years) were included who had disease progression after CPT-11/bolus FA/5-FU (Saltz; 7 patients, g…

Malemedicine.medical_specialtyAntimetabolites AntineoplasticPalliative careTime FactorsOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinSalvage therapyAntineoplastic AgentsIrinotecanGastroenterologyFolinic acidInternal medicineMucositisMedicineHumansNeoplasm MetastasisInfusions IntravenousAgedRetrospective StudiesSalvage TherapyChemotherapybusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicOxaliplatinSurgeryIrinotecanOxaliplatinFluorouracilCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct

Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma.

2006

It is well established that cancer arises in chronically inflamed tissue, and this is particularly notable in the gastrointestinal tract. Classic examples include Helicobacter pylori-associated gastric cancer, hepatocellular carcinoma, and inflammatory bowel disease-associated colorectal cancer. Growing evidence suggests that these associations might be not casual findings. Focusing on individual cytokines has generated evidence that anti-inflammatory cytokine interleukin (IL)-10 and transforming growth factor-beta1 (TGF-beta1) may have a complex role in gastrointestinal carcinogenesis. As an example, IL-10-deficient mice develop severe atrophic gastritis and a chronic enterocolitis, develo…

gene polymorphismsMaleRiskProlineColorectal cancerAtrophic gastritisil-10colorectal cancerMouse model of colorectal and intestinal cancerBiologymedicine.disease_causePolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyMetastasisTransforming Growth Factor beta1colorectal cancercytokine genepolymorphismsHistory and Philosophy of ScienceGene FrequencyLeucineGenotypemedicineHumansGenetic Predisposition to DiseaseAllelesGeneral Neurosciencetgf-β1CarcinomaCancermedicine.diseaseInterleukin-10Amino Acid SubstitutionItalyTumor progressionCase-Control StudiesImmunologycolorectal cancer; gene polymorphisms; il-10; tgf-β1FemaleCarcinogenesisColorectal NeoplasmsAnnals of the New York Academy of Sciences
researchProduct

Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?

2015

Objective Knowledge about determinants of participation in lifestyle interventions in cancer patients undergoing chemotherapy, particularly with palliative intent, remains poor. The objective of the present study was to identify determinants of participating in a 12 month individualized, comprehensive lifestyle intervention, focusing on diet, physical activity, mental stress and smoking cessation, in cancer patients receiving chemotherapy with curative or palliative intent. The secondary objective was to identify participation determinants 4 months into the study. Methods Newly diagnosed cancer patients starting chemotherapy at the cancer center in Kristiansand/Norway (during a 16 month inc…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentlcsh:MedicineAntineoplastic AgentsBreast NeoplasmsBreast cancerInternal medicinemedicineHumansPrecision Medicinelcsh:ScienceLife StyleSocioeconomic statusAgedChemotherapyMultidisciplinarybusiness.industryPalliative Carelcsh:RProstatic NeoplasmsCancerMiddle Agedmedicine.diseaseCombined Modality TherapyPhysical therapySmoking cessationMarital statusFemaleSmoking Cessationlcsh:QColorectal NeoplasmsbusinessBody mass indexResearch ArticlePLOS ONE
researchProduct

Colorectal Cancer Stem Cells: From the Crypt to the Clinic

2014

Since their first discovery, investigations of colorectal cancer stem cells (CSCs) have revealed some unexpected properties, including a high degree of heterogeneity and plasticity. By exploiting a combination of genetic, epigenetic, and microenvironmental factors, colorectal CSCs metastasize, resist chemotherapy, and continually adapt to a changing microenvironment, representing a formidable challenge to cancer eradication. Here, we review the current understanding of colorectal CSCs, including their origin, relationship to stem cells of the intestine, phenotypic characterization, and underlying regulatory mechanisms. We also discuss limitations to current preclinical models of colorectal …

Pluripotent Stem CellsColorectal cancerAnimals; Colonic Neoplasms; Colorectal Neoplasms; Disease Models Animal; Gene Expression Regulation Neoplastic; Humans; Intestines; Neoplastic Stem Cells; Pluripotent Stem Cells; Tumor EscapeCryptAnimals; Colonic Neoplasms; Colorectal Neoplasms; Disease Models Animal; Gene Expression Regulation Neoplastic; Humans; Intestines; Neoplastic Stem Cells; Pluripotent Stem Cells; Tumor Escape; Molecular Medicine; Genetics; Cell BiologyBiologySettore MED/04 - PATOLOGIA GENERALEmedicineGeneticsAnimalsHumansEpigeneticsRegulation of gene expressionNeoplasticAnimalCancerCell Biologymedicine.diseasePhenotypeGene Expression Regulation NeoplasticIntestinesDisease Models AnimalTumor EscapeGene Expression RegulationImmunologyColonic NeoplasmsDisease ModelsCancer researchNeoplastic Stem CellsMolecular MedicineTumor EscapeStem cellColorectal Neoplasmscolorectal cancer stem cells CSCsCell Stem Cell
researchProduct

Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases : a population-based study

2020

Background This population‐based study aimed to examine the incidence, patterns and results of multimodal management of metastatic colorectal cancer. Methods A retrospective population‐based study was conducted on patients with metastatic colorectal cancer in Central Finland in 2000–2015. Clinical and histopathological data were retrieved and descriptive analysis was conducted to determine the pattern of metastatic disease, defined as synchronous, early metachronous (within 12 months of diagnosis of primary disease) and late metachronous (more than 12 months after diagnosis). Subgroups were compared for resection and overall survival (OS) rates. Results Of 1671 patients, 296 (17·7 per cent)…

MaleLung NeoplasmsPROGNOSISColorectal cancerGastroenterology0302 clinical medicineEpidemiologyEPIDEMIOLOGYStage (cooking)FinlandAged 80 and overeducation.field_of_studyIncidenceIncidence (epidemiology)Liver NeoplasmsGeneral MedicineMiddle Aged3. Good healthSurvival Ratemedicine.anatomical_structureHPB030220 oncology & carcinogenesisSURVIVALLower GIFemaleOriginal Article030211 gastroenterology & hepatologysyöpätauditMetastasectomyColorectal Neoplasmsmedicine.medical_specialtyRESECTIONesiintyvyysPopulationlcsh:Surgerycolorectal cancersuolistosyövätLIVER METASTASESetäpesäkkeet03 medical and health sciencesInternal medicinemedicineHumanseducationAgedRetrospective StudiespaksusuolisyöpäLungbusiness.industryMetastasectomyRetrospective cohort studyOriginal Articleslcsh:RD1-8113126 Surgery anesthesiology intensive care radiologymedicine.diseasebusiness
researchProduct

Colorectal cancer stage at diagnosis in migrants versus non-migrants (KoMigra) : study protocol of a cross-sectional study in Germany

2014

Background: In Germany, about 20% of the total population have a migration background. Differences exist between migrants and non-migrants in terms of health care access and utilisation. Colorectal cancer is the second most common malignant tumour in Germany, and incidence, staging and survival chances depend, amongst other things, on ethnicity and lifestyle. The current study investigates whether stage at diagnosis differs between migrants and non-migrants with colorectal cancer in an area of high migration and attempts to identify factors that can explain any differences. Methods/Design: Data on tumour and migration status will be collected for 1,200 consecutive patients that have receive…

MaleCancer Researchmedicine.medical_specialtyCross-sectional studyLogistic regressionMigrantsHealth Services AccessibilityStudy ProtocolCross-sectionalGermanySurveys and QuestionnairesObservational studyHealth careEthnicityGeneticsHumansMedicineProspective Studiesddc:610Hard-to-reach populationProspective cohort studySocioeconomic statusAgedNeoplasm StagingTransients and MigrantsGynecologybusiness.industryOdds ratioMiddle AgedColorectal cancerCross-Sectional StudiesOncologyHealth care accessHard-to-reach population ; Ethnicity ; Observational study ; Migrants ; Colorectal cancer ; Health care access ; Cross-sectionalFemaleObservational studyOrdered logitColorectal NeoplasmsbusinessDemography
researchProduct

Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.

2014

Purpose Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and second-line metastatic colorectal cancer (mCRC). However, to date, there is no current biomarker predictive for the benefit of bevacizumab use for these patients. Preclinical data suggest that the presence of the primary tumor could be involved in less efficient antitumor activity of antiangiogenic agents, but no clinical data currently support this hypothesis. Methods We performed a retrospective analysis of factors associated with overall survival (OS) in a study cohort of 409 mCRC patients. Univariate and multivariate Cox proportional hazard regression models were used to assess the infl…

OncologyAdultMalemedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancerAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDeoxycytidineCapecitabineSurgical oncologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesNeoplasm MetastasisSurvival rateCapecitabineAgedNeoplasm StagingRetrospective StudiesAged 80 and overColorectal Cancerbusiness.industryMiddle Agedmedicine.diseasePrognosisPrimary tumorCombined Modality TherapyBevacizumabOxaliplatinSurvival RateOncologyAdenocarcinomaBiomarker (medicine)SurgeryCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnnals of surgical oncology
researchProduct

Chromoendoscopy in Inflammatory Bowel Disease

2012

Chromoendoscopy with methylene blue or indigo carmine significantly increases the diagnostic yield of finding intraepithelial neoplasia in patients with longstanding colitis. The number needed to treat is 14 for panchromoendoscopy to identify 1 additional patient with dysplasia. Chromoendoscopy can greatly facilitate the identification of flat lesions harboring intraepithelial neoplasia. Chromoendoscopy can guide biopsies and clearly reduces the amount of biopsies that are needed per patient. Magnifying endoscopy or CLE are additional techniques, which can be used in conjunction with chromoendoscopy to further reduce the amount of biopsies and to further increase the diagnostic yield. Chrom…

Adenomamedicine.medical_specialtyIntraepithelial neoplasiamedicine.diagnostic_testbusiness.industryfungiGastroenterologymedicine.diseaseGastroenterologyUlcerative colitisInflammatory bowel diseaseEndoscopy GastrointestinalEndoscopyChromoendoscopyDysplasiaInternal medicinePractice Guidelines as TopicEndomicroscopyHumansMedicineColitis UlcerativeColitisColorectal NeoplasmsColoring AgentsbusinessGastroenterology Clinics of North America
researchProduct

TRIPLET SCHEDULE OF WEEKLY 5-FLUOROURACIL AND ALTERNATING IRINOTECAN OR OXALIPLATIN IN ADVANCED COLORECTAL CANCER: A DOSE-FINDING AND PHASE II STUDY.

2010

A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose- finding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsMaximum Tolerated DoseOrganoplatinum CompoundsSettore MED/06 - Oncologia Medica5-FluorouracilPhases of clinical researchIrinotecanGastroenterologyInternal medicineCPT-11Antineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdvanced colorectal cancerAgedDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseOxaliplatinIrinotecanOxaliplatinSurvival RateRegimenTreatment OutcomeOncologyTolerabilityFluorouracilLymphatic MetastasisToxicityl-OHPCamptothecinFemaleFluorouracilbusinessColorectal NeoplasmsFebrile neutropeniamedicine.drug
researchProduct